MTT for Children With ASD Who Have Gastrointestinal Disorders

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Autism Spectrum Disorder, Gastro-Intestinal Disorder, Constipation, Diarrhea

In brief

The investigators propose to investigate Microbiota Transfer Therapy (MTT) for treating children with Autism Spectrum Disorder (ASD) and gastrointestinal problems (primarily constipation and/or diarrhea). MTT involves a combination of 10 days of oral vancomycin (an antibiotic to kill pathogenic bacteria), followed by a bowel cleanse, followed by 12 weeks of Fecal Microbiota (FM).

Key facts

Study ID
NCT04182633
Run by
Arizona State University
People needed
50
Starts
2019-11-15
Expected to finish
2025-12-30
Last updated by the study team
2025-04-25

Who can join

Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.